Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs-Massachusetts, 2015-2018.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: American Public Health Association Country of Publication: United States NLM ID: 1254074 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1541-0048 (Electronic) Linking ISSN: 00900036 NLM ISO Abbreviation: Am J Public Health Subsets: MEDLINE
    • Publication Information:
      Publication: Washington, DC : American Public Health Association
      Original Publication: New York [etc.]
    • Subject Terms:
    • Abstract:
      Objectives. To describe and control an outbreak of HIV infection among people who inject drugs (PWID). Methods. The investigation included people diagnosed with HIV infection during 2015 to 2018 linked to 2 cities in northeastern Massachusetts epidemiologically or through molecular analysis. Field activities included qualitative interviews regarding service availability and HIV risk behaviors. Results. We identified 129 people meeting the case definition; 116 (90%) reported injection drug use. Molecular surveillance added 36 cases to the outbreak not otherwise linked. The 2 largest molecular groups contained 56 and 23 cases. Most interviewed PWID were homeless. Control measures, including enhanced field epidemiology, syringe services programming, and community outreach, resulted in a significant decline in new HIV diagnoses. Conclusions. We illustrate difficulties with identification and characterization of an outbreak of HIV infection among a population of PWID and the value of an intensive response. Public Health Implications. Responding to and preventing outbreaks requires ongoing surveillance, with timely detection of increases in HIV diagnoses, community partnerships, and coordinated services, all critical to achieving the goal of the national Ending the HIV Epidemic initiative.
    • References:
      Clin Infect Dis. 2017 Apr 1;64(7):860-869. (PMID: 28362947)
      Subst Use Misuse. 2018 Feb 23;53(3):457-465. (PMID: 29035611)
      AIDS. 2016 Mar 27;30(6):815-26. (PMID: 26836787)
      N Engl J Med. 2015 Jul 30;373(5):397-9. (PMID: 26106947)
      JAMA. 2019 Mar 5;321(9):844-845. (PMID: 30730529)
      MMWR Morb Mortal Wkly Rep. 2011 May 6;60(17):537-41. (PMID: 21544042)
      Top Antivir Med. 2016 Jul/Aug;24(2):90-92. (PMID: 27841978)
      J Urban Health. 2015 Aug;92(4):650-66. (PMID: 26022666)
      MMWR Morb Mortal Wkly Rep. 2019 Jan 18;68(2):41-43. (PMID: 30653486)
      JAMA. 2018 Apr 24;319(16):1657-1658. (PMID: 29630701)
      Int J Drug Policy. 2017 Aug;46:146-155. (PMID: 28735775)
      N Engl J Med. 2016 Jul 21;375(3):229-39. (PMID: 27468059)
      Addiction. 2007 Sep;102(9):1454-62. (PMID: 17697278)
      Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021. (PMID: 28922449)
      MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):344-349. (PMID: 30998671)
      J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):543-550. (PMID: 30222659)
    • Accession Number:
      0 (pol Gene Products, Human Immunodeficiency Virus)
    • Publication Date:
      Date Created: 20191115 Date Completed: 20200427 Latest Revision: 20221207
    • Publication Date:
      20240105
    • Accession Number:
      PMC6893347
    • Accession Number:
      10.2105/AJPH.2019.305366
    • Accession Number:
      31725317